2025年12月6日，一场汇聚中外医学智慧、跨越学科边界的学术盛会——"人体复杂系统运行规律及疑难 疾病临床决策研讨会"通过线上方式隆重举行。本次会议由中国生物多样性与绿色发展基金会肿瘤生态 委员会、中国老年保健协会肿瘤支持专业委员会牵头，联合中国慈善总会科技与文化发展委员会、中国 科学院数学与系统科学研究院、北京中西医慢病防治学会、经方与现代中药融合创新全国重点实验室、 肿瘤智库主动健康与疑难杂症临床决策中心、轻又清微生态健康食品研发中心、青岛普罗吉有限公司等 多家权威机构共同主办。会议上，基于创新理论构建的"肿瘤智库复杂疾病决策平台"——肿瘤生态学一 站式诊疗平台上线，标志着针对癌症中晚期、慢性病等复杂疾病的诊疗，开始从传统的"分科对抗"模 式，转向"系统调控、生态重建"的新范式。 会议提出的"人体复杂系统运行规律与疑难复杂疾病临床决策理论体系"认为，人体应被理解为一个具备 多层反馈、高度整合的智能生态系统，通过精密调节维持动态平衡。而疾病，尤其是疑难复杂疾病，是 跨尺度（从基因到环境）、动态演进中的"系统失稳"过程，远非单一器官的故障。 会议认为，必须打破传统以症状和器官为中心的疾病分类束缚，构建融合遗 ...

Core Points - The "Hong Kong-Macao Drug and Medical Device Pass" has designated a total of 71 medical institutions in Guangdong Province as of December 8, 2023 [1][2] - The fourth batch of designated hospitals includes 27 new medical institutions, such as the Southern Medical University Zhujiang Hospital [1] - Since the implementation of the "Hong Kong-Macao Drug and Medical Device Pass" in 2021, a total of 140 varieties of drugs and medical devices have been approved for import, benefiting approximately 17,000 patients [2] Summary by Sections Implementation and Designation - The "Hong Kong-Macao Drug and Medical Device Pass" was officially implemented in Guangdong Province in 2021, with the first three batches of designated medical institutions announced in August 2021, February 2023, and September 2024 [2] - The recent announcement includes 27 new hospitals, bringing the total to 71 designated institutions [1][2] Regulatory and Operational Aspects - The Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration have mandated that designated medical institutions enhance supervision and management, deepen cooperation with Hong Kong and Macao in medical services, and ensure the safety of imported drugs and medical devices [1] - The institutions are required to continuously improve the relevant systems of the "Hong Kong-Macao Drug and Medical Device Pass" [1] Patient Impact - The approved imports include 63 types of drugs and 77 types of medical devices, which have collectively served around 17,000 patients [2]

绿色经济(01315)发布公告，于2025年9月15日至9月17日，集团已于公开市场出售所有投资者股份(公司 全资附属公司加华认购的274.86万股佰泽医疗股份)，总代价约为3020万港元。于出售事项完成后，公 司将不再于佰泽医疗拥有任何投资。 ...

此外，合富中国表示，公司控股股东合富(香港)控股有限公司存在减持计划，截至12月8日，控股股东 尚未减持，公司不存在应披露而未披露的重大事项。 北京商报讯(记者丁宁)12月8日晚间，当日涨停收盘的合富中国（603122）发布公告称，公司股票价格 于12月4日、12月5日及12月8日连续三个交易日内日收盘价格涨幅偏离值累计超过20%，根据上交所的 有关规定，属于股票交易异常波动情形。 合富中国表示，公司股价累计涨幅已严重偏离基本面，投资者参与交易可能面临较大风险。自10月28日 至12月8日，公司股票有十六个交易日以涨停价收盘，并6次触及股价异常波动、3次触及严重异常波动 情形，期间累计涨幅高达336.83%。截至12月8日收盘，公司股价为29.18元/股，处于历史最高位。股价 短期内连续上涨，存在市场情绪过热、非理性炒作风险，已明显高于同期行业及上证指数涨幅，且严重 显著偏离公司基本面，随时存在快速下跌风险。 ...

锦欣生殖(01951)发布公告，于2025年12月8日，该公司斥资1484.91万港元回购592.85万股股份，每股回 购价格为2.47-2.58港元。 ...

Core Viewpoint - The company, Meizhong Jiahe (02453), announced that its subsidiary, Guangzhou Taihe Oncology Hospital, has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its capabilities in oncology treatment and competitive advantage in the market [1] Group 1: Regulatory Approval - Guangzhou Taihe Oncology Hospital received approval from the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration on December 8, 2025, to be included in the designated medical institution list for the Guangdong-Hong Kong-Macao Greater Bay Area [1] - The "Hong Kong-Macao Drug and Medical Device Access" initiative is a key measure under the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [1] Group 2: Business Expansion - The qualification allows the company to import and use urgently needed drugs and advanced medical devices that have been approved in Hong Kong and Macao but not yet in mainland China [1] - This move will enable the company to introduce innovative oncology drugs and expand its business boundaries, creating a differentiated competitive advantage in the oncology market [1] Group 3: Clinical and Research Enhancement - The initiative will facilitate deeper integration with Hong Kong and Macao medical resources, improving clinical diagnosis and treatment levels as well as research capabilities [1] - By introducing cutting-edge medical devices and optimizing oncology treatment plans, the company aims to align with international medical standards and enhance the overall patient service experience and treatment outcomes [1]

本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 自願公告 公司獲批進入「港澳藥械通」指定醫療機構名單 承董事會命 美中嘉和醫學技術發展集團股份有限公司 董事長兼執行董事 楊建宇 董事會欣然宣佈，本公司子公司廣州泰和腫瘤醫院於2025年12月8日，獲廣東省 衛生健康委員會與廣東省藥品監督管理局批准進入粵港澳大灣區「港澳藥械通」指 定醫療機構名單。 「港澳藥械通」是《粵港澳大灣區藥品醫療器械監管創新發展工作方案》的核心落地 舉措，進入名單的粵港澳大灣區的指定醫療機構，可經審批進口使用粵港澳大灣 區專項醫藥政策，允許指定醫療機構經審批使用港澳已上市的臨床急需藥品及具 有先進性的醫療器械。 本 ...

Core Viewpoint - The article discusses the issuance of the "Guidelines for the Pricing of Surgical and Treatment Auxiliary Operations" by the National Medical Insurance Administration, which aims to standardize and categorize auxiliary surgical operations within the medical insurance system, enhancing transparency and adaptability to new technologies [2][3]. Policy Background - The introduction of a unified pricing guideline addresses structural challenges in China's medical service pricing system, such as regional disparities and the lack of standardized pricing for auxiliary operations [3]. - The guidelines represent the first systematic classification of auxiliary operations in surgery, covering advanced technologies like 3D imaging, navigation systems, and remote surgery [3][4]. Key Components of the Guidelines - The pricing project consists of seven core elements: project name, service output, price composition, additional charges, expansion items, pricing units, and pricing explanations [4]. - The guidelines include 36 auxiliary operations categorized into six systems based on service output attributes, facilitating understanding across disciplines [5][6]. Categories of Auxiliary Operations - **3D Technology Chain**: This category includes operations related to 3D reconstruction, modeling, and printing, which enhance pre-surgical planning and individualization of treatment [6][8]. - **Tracing and Imaging Enhancement**: This category focuses on technologies that improve intraoperative information clarity, such as tracers and advanced imaging techniques [7][9]. - **Energy Instrument Assistance**: This category includes various energy devices used in surgery, emphasizing the separation of technical costs from device usage [10][11]. - **Intraoperative Imaging Guidance**: This category standardizes the pricing of imaging guidance during surgery, enhancing its role in risk management [12][13]. - **Surgical Path Navigation**: This category includes navigation systems that provide real-time tracking and positioning during surgeries [14][15]. - **Surgical Robotics and Remote Surgery**: This category recognizes the role of robotic assistance and remote surgery as significant advancements in surgical capabilities [16][18]. Understanding the Pricing System - The guidelines emphasize that "service output" is the sole basis for establishing pricing projects, allowing for flexibility in technical paths as long as the output remains consistent [20]. - The guidelines allow for existing projects to accommodate technological improvements without the need for new pricing applications, reducing barriers to innovation [21][22]. Implications for Hospitals and Enterprises - The new pricing framework is expected to lead to a comprehensive restructuring of cost management, quality control, and payment mechanisms within hospitals [26][30]. - Hospitals will be better equipped to assess the real costs and values of auxiliary operations, promoting transparency and accountability in surgical practices [30][31]. - Enterprises will need to shift their focus from equipment-centric models to service output-oriented strategies, enhancing their data capabilities to comply with new regulatory requirements [36][38]. Observations on Systemic Evolution - The guidelines represent a significant shift from fragmented technical approaches to a cohesive capability system, facilitating clearer communication of technological value [44][45]. - The formal recognition of independent pricing for capabilities, such as robotic assistance, aligns with international trends towards technology-neutral and capability-oriented regulatory frameworks [46]. - The requirement for data retention and reporting will transform surgical practices from experience-based to data-driven methodologies, supporting future research and clinical improvements [47][48].

合富中国公告称，公司股票于2025年12月4日、5日及8日连续三个交易日涨幅偏离值累计超20%，属异 常波动。10月28日至12月8日累计涨幅336.83%，16个交易日涨停，6次触及异常波动、3次触及严重异 常波动。截至12月8日，股价29.18元/股创历史新高，静态市盈率421.35倍，远高于行业的28.86倍。 2025年第三季度净利润为 -504.80万元，同比降225.26%。控股股东有减持计划，但截至12月8日尚未减 持，提醒投资者注意风险。 ...

Core Viewpoint - Tongce Medical (600763) has shown a slight decline in stock price and mixed capital flow, indicating potential investor caution and varying interest from different types of investors [1][2]. Group 1: Stock Performance - As of December 8, 2025, Tongce Medical closed at 41.74 CNY, down 0.1% with a turnover rate of 0.7% and a trading volume of 31,500 lots, amounting to a total transaction value of 132 million CNY [1]. - Over the past five days, the stock has experienced fluctuations in price and capital flow, with a notable net outflow of 1,098.88 million CNY on December 8, 2025, which accounted for 8.35% of the total transaction value [2]. Group 2: Financial Metrics - Tongce Medical's total market capitalization is 18.67 billion CNY, with a net asset value of 4.703 billion CNY and a net profit of 514 million CNY, ranking 8th, 12th, and 6th respectively within the medical services industry [3]. - The company reported a year-on-year revenue increase of 2.56% for the first three quarters of 2025, totaling 2.29 billion CNY, with a net profit of 514 million CNY, reflecting a 3.16% increase [3]. Group 3: Institutional Ratings - In the last 90 days, eight institutions have provided ratings for Tongce Medical, with five giving a "buy" rating and three an "increase" rating, while the average target price set by institutions is 52.88 CNY [4].